Insmed Incorporated (INSM) Earnings: An Early Look

Insmed Incorporated (NASDAQ: INSM)Earnings season is winding down, with most companies already having reported their quarterly results. But there are still some companies left to report, and Insmed Incorporated (NASDAQ:INSM) is about to release its quarterly earnings report. The key to making smart investment decisions with stocks releasing their quarter reports is to anticipate how they’ll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you’ll be less likely to make an uninformed kneejerk reaction to news that turns out to be exactly the wrong move.

Insmed Incorporated (NASDAQ:INSM) is a small biotech with big aspirations, as it aims to come up with treatments for niche lung diseases. With a promising inhaled therapy in late-stage trials, Insmed is hoping to hit the big leagues in the near future. Let’s take an early look at what’s been happening with Insmed Incorporated (NASDAQ:INSM) over the past quarter and what we’re likely to see in its quarterly report on Monday.

Stats on Insmed

Analyst EPS Estimate ($0.33)
Year-Ago EPS ($0.30)
Revenue Estimate $0
Year-Ago Revenue $1.4 million
Earnings Beats in Past 4 Quarters 3

Source: Yahoo! Finance.

Will Insmed breathe easier this quarter?
Analysts have gotten some more optimistic about Insmed’s earnings prospects in recent months. They’ve reined in their loss estimates by $0.02 per share for the just-ended quarter and by a dime for full-year 2013, but Insmed Incorporated (NASDAQ:INSM) still has a long way to go before it can expect to generate any revenue. That’s likely one reason why the shares have been largely stuck in neutral, rising about 4% since mid-December.

Insmed has had a long and storied history. For more than a decade, the company has struggled to get a product on the market, but so far, FDA approval has eluded all of its best attempts. With the repeated need to come back to the capital markets for new financing through secondary offerings, most recently last September with the sale of 6.3 million shares to three investors at $4.07 per share, Insmed Incorporated (NASDAQ:INSM)’s stock has lost more than 95% of its value over a 13-year span.

Yet more recently, Insmed has seen its prospects rise. Its Arikace treatment is being studied to treat lung infections for cystic-fibrosis patients and other lung problems, and a clinical trial halt back in 2011 has been lifted, allowing phase 3 trials to continue. The inhaled treatment allows for once-daily dosing, which is an improvement over current twice-daily medications. Novartis AG (ADR) (NYSE:NVS) has turned its inhaled tobramycin Tobi into a successful treatment addressing a $1 billion market, but if Arikace proves superior and gains approval, Novartis may end up ceding that market to Insmed.

Insmed saw its chief scientific officer resign in October, raising some concerns about the prospects for the company’s development program going forward. But with data expected on the cystic fibrosis trial later this year, an application for FDA approval could be forthcoming.

In its quarterly report, look for Insmed Incorporated (NASDAQ:INSM) to detail any plans it has for expanding the potential target area for Arikace beyond its current indications. The more uses it can find, the better its prospects to gain approval in the long run.

The article Insmed Earnings: An Early Look originally appeared on Fool.com and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Top Reasons For Getting Fired

The 3 Best States to Start an LLC

10 Jobs That Allow You to Travel

7 High-Paying Jobs You Can Do From Home

12 Best Cities to Shop in USA

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!